Trial Profile

A Multicenter, Open-label Study of CMX001 Treatment of Serious Diseases or Conditions Caused by Double-stranded DNA Viruses

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 17 Aug 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Brincidofovir (Primary)
Indications DNA virus infections
Focus Therapeutic Use
Sponsors Chimerix

Most Recent Events

08 Sep 2014 Results published in the Media Release.
31 Jul 2014 Results in subset of renal transplant patients presented at the 2014 World Transplant Congress.
31 Jul 2014 Results in subset of patients switching from cidofovir or foscarnet presented at the 2014 World Transplant Congress.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com